Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | DHFR | P00374 | 4/20 | 0.34 |
| ▸ | DCPS | Q96C86 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22959044 | 1.00 | KCNH2 (0.52) | KCNH2HSP90AB1CYP2D6TLR8TLR7 | |
| SCHEMBL22959033 | 0.91 | KCNH2 (0.46) | KCNH2HSP90AB1CYP2D6DHFRDCPS | |
| SCHEMBL22959045 | 0.89 | KCNH2 (0.52) | KCNH2HSP90AB1CYP2D6TLR8TLR7 | |
| SCHEMBL22958971 | 0.89 | KCNH2 (0.52) | KCNH2HSP90AB1CYP2D6TLR8TLR7 | |
| SCHEMBL22959008 | 0.77 | KCNH2 (0.46) | KCNH2HSP90AB1CYP2D6TLR8TLR7 | |
| SCHEMBL22959041 | 0.72 | KCNH2 (0.40) | KCNH2HSP90AB1DHFRDCPS | |
| SCHEMBL22958979 | 0.70 | KCNH2 (0.41) | KCNH2HSP90AB1CYP2D6DHFRDCPS | |
| SCHEMBL22958969 | 0.70 | KCNH2 (0.38) | KCNH2HSP90AB1DHFRDCPS | |
| SCHEMBL24384584 | 0.69 | KCNH2 (0.85) | KCNH2CYP2D6TLR8TLR7 | |
| SCHEMBL24384693 | 0.69 | KCNH2 (0.85) | KCNH2CYP2D6TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2023-09-07 | — | — | US | disclosed |
| US-20210040046-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimi (IE) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040046-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | HRH4, HRH3, HNMT | KCNH2 968/4885HSP90AB1 4226/4885CYP2D6 32/4885 |
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | QDPR, PADI2, PEPD | KCNH2 1977/4885HSP90AB1 3596/4885CYP2D6 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.